CIPROFLOXACIN HYDROCHLORIDE

Post-LOE

ciprofloxacin hydrochloride

Rubicon Biotechnology

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Jun 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CIPROFLOXACIN HYDROCHLORIDE (ciprofloxacin hydrochloride) by Rubicon Biotechnology is clinical pharmacology: systemic absorption: a systemic absorption study was performed in which ciprofloxacin ophthalmic solution was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. Approved for infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: acute otitis media (aom) in pediatric patients (age 6 months, older) with tympanostomy tubes due to staphylococcus aureus, streptococcus pneumoniae and 3 more indications. First approved in 2004.

Drug data last refreshed 22h ago

Mechanism of Action

CLINICAL PHARMACOLOGY: Systemic Absorption: A systemic absorption study was performed in which ciprofloxacin ophthalmic solution was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. The maximum reported plasma…

Worked on CIPROFLOXACIN HYDROCHLORIDE at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CIPROFLOXACIN HYDROCHLORIDE

Mechanism of Action

Indications (6)